Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.49 |
| ▸ | PDE2A | O00408 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | VNN1 | O95497 | 3/20 | 0.45 |
| ▸ | BTD | P43251 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4228255 | 1.00 | HSD11B1 (0.53) | HSD11B1KMT2AMEN1CHRM5PDE2A | |
| SCHEMBL1968059 | 0.85 | NPC1 (0.54) | HSD11B1KMT2AMEN1ALDH1A1 | |
| SCHEMBL1968055 | 0.85 | NPC1 (0.54) | HSD11B1KMT2AMEN1ALDH1A1 | |
| SCHEMBL3390856 | 0.81 | KMT2A (0.55) | HSD11B1KMT2AMEN1PDE2ALMNA | |
| SCHEMBL3390861 | 0.81 | KMT2A (0.55) | HSD11B1KMT2AMEN1PDE2ALMNA | |
| SCHEMBL1972867 | 0.80 | VNN1 (0.53) | KMT2AMEN1PDE2ALMNAALDH1A1 | |
| SCHEMBL1972864 | 0.80 | VNN1 (0.53) | KMT2AMEN1PDE2ALMNAALDH1A1 | |
| SCHEMBL5031105 | 0.79 | HSD11B1 (0.55) | HSD11B1KMT2AMEN1PDE2ALMNA | |
| SCHEMBL3578454 | 0.78 | GLA (0.70) | HSD11B1KMT2AMEN1PDE2AALDH1A1 | |
| SCHEMBL3578457 | 0.78 | GLA (0.70) | HSD11B1KMT2AMEN1PDE2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215822-A1 | Substituted Oxadiazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | NIKEM RESEARCH SRL (IT) | 2009-08-27 | — | — | US | disclosed |
| EP-1893606-A2 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma SA (CH) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006123255-A2 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215822-A1 | Substituted Oxadiazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | GRM5, GRM3, GRM2 | HSD11B1 3080/4885KMT2A 2226/4885MEN1 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.